Effectiveness of empirical Helicobacter pylori eradication therapy with furazolidone in Russia: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

封面

如何引用文章

全文:

详细

Background. First-line therapy does not always provide a high level of Helicobacter pylori eradication due to the increase of H. pylori resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical H. pylori furazolidone-containing regimens.

Materials and methods. Adult H. pylori infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on H. pylori management (Hp-EuReg). Data were collected at AEG-REDCap e-CRF from 2013 to 2021 and the quality was reviewed. Modified intention-to-treat (mITT) effectiveness analyses were performed.

Results. Overall 106 patients received empirical furazolidone-containing therapy in Russia. Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9.4%). Treatment duration of 7 days was assigned to 2 (1.9%) patients, 10-day eradication therapy in case of 80 (75%) and 14 days – in 24 (23%) patients. Furazolidone was mainly used in first- (79%) and second-line (21%) regimens. The methods used to diagnose H. pylori infection were: histology (81%), stool antigen test (64%), 13C-urea breath test (6.6%), and rapid urease test (1.9%). The mITT effectiveness of sequential therapy was 100%; 93% with the triple therapy and 75.5% with quadruple therapy. Compliance was reported in 98% of cases. Adverse events were revealed in 5.7% of patients, mostly nausea (3.8%). No serious adverse events were reported.

Conclusion. Furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.

作者简介

Dmitry Bordin

Loginov Moscow Clinical Scientific Center; Yevdokimov Moscow State University of Medicine and Dentistry; Tver State Medical University

编辑信件的主要联系方式.
Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-2815-3992

д-р мед. наук, зав. отд. патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта, проф. каф. пропедевтики внутренних болезней и гастроэнтерологии, проф. каф. общей врачебной практики и семейной медицины фак-та дополнительного профессионального образования

俄罗斯联邦, Moscow; Moscow; Tver

Irina Voynovan

Loginov Moscow Clinical Scientific Center

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-5584-8514

канд. мед. наук, науч. сотр. отд-ния патологии верхних отделов пищеварительного тракта

俄罗斯联邦, Moscow

Aiman Sarsenbaeva

South Ural State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0001-5922-2271

д-р мед. наук, проф. каф. терапии, декан Института дополнительного профессионального образования

俄罗斯联邦, Chelyabinsk

Oleg Zaytsev

First Clinical Medical Centre

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-5878-5280

врач-гастроэнтеролог, вед. специалист рук. терапевтического центра

俄罗斯联邦, Kovrov

Rustam Abdulkhakov

Kazan State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-1509-6776

д-р мед. наук, проф., проф. каф. госпитальной терапии

俄罗斯联邦, Kazan

Natalia Bakulina

Mechnikov North-Western State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-4075-4096

д-р мед. наук, зав. каф. терапии, клинической фармакологии и нефрологии

俄罗斯联邦, Saint Petersburg

Igor Bakulin

Mechnikov North-Western State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-6151-2021

д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

俄罗斯联邦, Saint Petersburg

Marina Osipenko

Novosibirsk State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-5156-2842

д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней

俄罗斯联邦, Novosibirsk

Maria Livzan

Omsk State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-6581-7017

чл.-кор. РАН, д-р мед. наук, проф., зав каф. факультетской терапии, ректор

俄罗斯联邦, Omsk

Sergei Alekseenko

Far Eastern State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-1724-9980

д-р мед. наук, проф., зав. каф. госпитальной терапии

俄罗斯联邦, Khabarovsk

Larisa Tarasova

Ulianov Chuvash State University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-1496-0689

д-р мед. наук, зав. каф. факультетской и госпитальной терапии

俄罗斯联邦, Cheboksary

Galina Tarasova

Rostov State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-4054-9180

д-р мед. наук, проф., проф. каф. пропедевтики внутренних болезней

俄罗斯联邦, Rostov-on-Don

Pavel Bogomolov

Yevdokimov Moscow State University of Medicine and Dentistry; Private Medical Center “Universal”; Vladimirsky Moscow Regional Clinical Research Institute

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-2346-1216

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии, врач-гастроэнтеролог, рук. отд-ния и вед. науч. сотр. гепатологического отд-ния

俄罗斯联邦, Moscow; Moscow; Moscow

Igor Maev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: d.bordin@mknc.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии

俄罗斯联邦, Moscow

Dmitry Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-4007-7112

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии, науч. сотр. лаб. функциональных методов исследования в гастроэнтерологии

俄罗斯联邦, Moscow

Sayar Abdulkhakov

Kazan State Medical University; Kazan Federal University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0001-9542-3580

канд. мед. наук, доц., доц. каф. поликлинической терапии и общей врачебной практики, зав. каф. внутренних болезней, ст. науч. сотр.

俄罗斯联邦, Kazan; Kazan

Boris Starostin

City Polyclinic №38

Email: d.bordin@mknc.ru

зав. Межрайонного гастроэнтерологического центра 1

俄罗斯联邦, Saint Petersburg

Natalia Bakanova

Medical Center “Medicea”

Email: d.bordin@mknc.ru
ORCID iD: 0000-0001-9724-0622

канд. мед. наук, зав. гастроэнтерологической службой, врач-гастроэнтеролог

俄罗斯联邦, Izhevsk

Alla Kononova

Tver State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-4525-0885

канд. мед. наук, доц. каф. поликлинической терапии и семейной медицины

俄罗斯联邦, Tver

Sergei Kolbasnikov

Tver State Medical University

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-9223-0457

д-р мед. наук, проф., зав. каф. поликлинической терапии и семейной медицины

俄罗斯联邦, Tver

Elena Bueverova

Sechenov First Moscow State Medical University (Sechenov University)

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-0700-9775

канд. мед. наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского

俄罗斯联邦, Moscow

Leticia Moreira

Hospital Clínic de Barcelona; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd); University of Barcelona

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-4518-8591

IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer)

西班牙, Barcelona; Madrid; Barcelona

Francis Megraud

Université de Bordeaux

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-2481-1612

Professor of Bacteriology

法国, Bordeaux

Colm O'Morain

Trinity College Dublin

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-1847-6782

Department of Gastroenterology, UEG President 2011–2013, Emeritus Professor of Medicine

爱尔兰, Dublin

Olga Perez Nyssen

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); Universidad Autónoma de Madrid (UAM)

Email: d.bordin@mknc.ru
ORCID iD: 0000-0002-4920-9310

Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa)

西班牙, Madrid; Madrid

Javier Perez Gisbert

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); Universidad Autónoma de Madrid (UAM)

Email: d.bordin@mknc.ru
ORCID iD: 0000-0003-2090-3445

Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa)

Madrid; Madrid

参考

  1. Mezmale L, Coelho LG, Bordin D, Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020;25 Suppl. 1:e12734. doi: 10.1111/hel.12734
  2. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153:420-9. doi: 10.1053/j.gastro.2017.04.022
  3. Borsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB (ed). Pharmacology of Peptic Ulcer Disease. Vol. 99. Berlin: Springer-Verlag, 1991; pp. 107-48 (Handbook of Experimental Pharmacology).
  4. Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. Am J Med. 2018;131(5):473-9. doi: 10.1016/j.amjmed.2017.12.024
  5. Smith SM. An update on the treatment of Helicobacter pylori infection. EMJ Gastroenterol. 2015;4:101-7.
  6. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/apt.13497
  7. Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012;61(5):646-64. doi: 10.1136/gutjnl-2012-302084
  8. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288
  9. Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007
  10. Nyssen OP, Vaira D, Tepes B, et al; Hp-EuReg Investigators. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). J Clin Gastroenterol. 2022;56(2):e98-e108. doi: 10.1097/MCG.0000000000001482
  11. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. doi: 10.1016/j.cgh.2019.03.048
  12. Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of Helicobacter pylori to furazolidone and levofloxacin: A viewpoint. World J Gastroenterol. 2017;23:6920-2. doi: 10.3748/wjg.v23.i37.6920
  13. Su Z, Xu H, Zhang C, et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J. 2006;47:410-5.
  14. Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therap Adv Gastroenterol. 2020;13:1756284820968736. doi: 10.1177/1756284820968736
  15. Liu WZ, Xie Y, Lu H, et al; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. doi: 10.1111/hel.12475
  16. Grayson Lindsay M, Crowe S, Crowe S (eds.), et al. Kucers' the use of antibiotics. 7th ed. Boca Raton, Florida, America: CRC press, 2017; рр. 3187-94. doi: 10.1201/9781498747967
  17. Zheng ZT, Wang ZY, Chu YX, et al. Double-blind short-term trial of furazolidone in peptic ulcer. Lancet. 1985;8436:1048-9.
  18. Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18(1):1-2. doi: 10.4103/1319-3767.91724
  19. McNicholl AG, O'Morain CA, Megraud F, Gisbert JP. As Scientific Committee of the Hp-Eureg on Behalf of the National C. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019;24(5):e12630. doi: 10.1111/hel.12630
  20. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010
  21. Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019;24(1):e12554. doi: 10.1111/hel.12554
  22. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19-31. doi: 10.1007/s00228-008-0576-5
  23. Щербаков П.Л., Вартапетова Е.Е., Филин В.А., Салмова В.С. Алгоритм современной диагностики и лечения хеликобактерной инфекции у детей с заболеваниями верхних отделов пищеварительного тракта. Педиатрия. Журнал им. Г.Н. Сперанского. 2003;82(6):86-90 [Shcherbakov PL, Vartapetova EE, Filin VA, Salmova VS. Algorithm for modern diagnosis and treatment of Helicobacter pylori infection in children with diseases of the upper digestive tract. Pediatrics. Journal G.N. Speransky. 2003;82(6):86-90 (in Russian)].
  24. Нижевич А.А., Щербаков П.Л., Сатаев В.У., и др. Эрадикация Helicobacter pylori у детей после неудачной попытки первичной терапии: преимущества использования нифурателя перед фуразолидоном в четырехкомпонентной схеме. Международный журнал терапии в гастроэнтерологии и гепатологии. 2005;22(9):881-7 [Nizhevich AA, Shcherbakov PL, Sataev VU. Eradication of Helicobacter pylori in children after failed primary therapy: advantages of using nifuratel over furazolidone in a four-component regimen. International Journal of Therapy in Gastroenterology and Hepatology. 2005;22(9):881-7 (in Russian)].
  25. Нижевич А.А., Сатаев В.У., Ахмадеева А.Г., и др. Тройная нифурател-содержащая антихеликобактерная терапия 1-й линии у детей. Helicobacter. 2007;12:132-5 [Nizhevich AA, Sataev VU, Akhmadeeva AG, et al. Triple nifuratel-containing first-line anti-Helicobacter therapy in children. Helicobacter. 2007;12:132-5 (in Russian)].
  26. Исаков В.А., Домарева И., Кудрявцева Л.В., и др. Сравнение эффективности фуразолидон-содержащей трехкомпонентной и четырехкомпонентной схем эрадикационной терапии при наличии резистентности Helicobacter pylori к метронидазолу. Aliment Pharmacol Ther. 2002;16:1277-82 [Isakov VA, Domareva I, Kudryavtseva LV, et al. Comparison of the effectiveness of furazolidone-containing three-component and four-component schemes of eradication therapy in the presence of Helicobacter pylori resistance to metronidazole. Aliment Pharmacol Ther. 2002;16:1277-82 (in Russian)].
  27. Machado RS, da Silva MR, Viriato A. Furazolidone, tetracycline and omeprazole: a low-cost alternative for Helicobacter pylori eradication in children. J Pediatr (Rio J). 2008;84(2):160-5. doi: 10.2223/JPED.1772
  28. Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Dig Dis Sci. 2017;62(8):1890-6. doi: 10.1007/s10620-017-4628-5
  29. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802-7.e1. doi: 10.1016/j.cgh.2013.01.008
  30. Xie Y, Zhu Y, Zhou H, et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol. 2014;20(32):11415-21. doi: 10.3748/wjg.v20.i32.11415
  31. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15:860-4. doi: 10.3748/wjg.15.860
  32. Ji CR, Liu J, Li YY, et al. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open. 2020;10(10):e037375. doi: 10.1136/bmjopen-2020-037375
  33. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis. Saudi J Gastroenterol. 2012;18(1):11-7. doi: 10.4103/1319-3767.91729
  34. Zhuge L, Wang Y, Wu S, et al. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter. 2018;23:e12468. doi: 10.1111/hel.12468
  35. Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24:4596-05. doi: 10.3748/wjg.v24.i40.4596
  36. Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter. 2019;24:e12591. doi: 10.1111/hel.12591
  37. Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571-81. doi: 10.1111/j.1440-1746.2007.05082.x
  38. Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel). 2021;10(9):1028. doi: 10.3390/antibiotics10091028
  39. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003;18:778-2. doi: 10.1046/j.1440-1746.2003.03058.x

版权所有 © Bordin D.S., Voynovan I.N., Sarsenbaeva A.S., Zaytsev O.V., Abdulkhakov R.A., Bakulina N.V., Bakulin I.G., Osipenko M.F., Livzan M.A., Alekseenko S.A., Tarasova L.V., Tarasova G.N., Bogomolov P.O., Maev I.V., Andreev D.N., Abdulkhakov S.R., Starostin B.D., Bakanova N.V., Kononova A.G., Kolbasnikov S.V., Bueverova E.L., Moreira L., Megraud F., O'Morain C., Perez Nyssen O., Gisbert J., 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 
 


##common.cookie##